0.697  0.037 (5.61%)		07-23 15:59
Open: 0.68 High: 0.84 Volume: 294,114		Pre. Close: 0.66 Low: 0.632 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	1.39	1-year :	1.81
Resists	First :	1.19	Second :	1.54
Pivot price	0.72
Supports	First :	0.61	Second :	0.51
MAs	MA(5) :	0.66	MA(20) :	0.76
	MA(100) :	3.94	MA(250) :	13.04
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	13.9	D(3) :	9.5
RSI	RSI(14): 33.3
52-week	High :	40.31	Low :	0.61

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ APUS ] has closed above bottom band by 41.4%. Bollinger Bands are 94.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 67 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.84 - 0.84	0.84 - 0.85
Low:	0.63 - 0.63	0.63 - 0.63
Close:	0.69 - 0.7	0.7 - 0.7

Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.

Tue, 21 Jul 2026
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Mon, 13 Jul 2026
Apimeds Pharmaceuticals US to implement 1-for-10 reverse stock split, new CUSIP 03771D201 - TradingView

Wed, 10 Jun 2026
Apimeds Pharmaceuticals US Inc. (APUS) Holds Near Support After 3.76% Decline - IPO Entry Watch - dars.gov.et

Tue, 05 May 2026
Apimeds settles disputes, stock to resume trading today - Investing.com

Sun, 26 Apr 2026
APUS Investors Have Opportunity to Join Apimeds - GlobeNewswire

Wed, 22 Apr 2026
Apimeds Pharmaceuticals US Received Notice of Noncompliance - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.